ArticleDiagnostics (Basel, Switzerland)2019
An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers.
Article in Diagnostics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Age- and Sex-Dependent Variation in the Type I Interferon Signature of Healthy Individuals.Medicina (Kaunas, Lithuania) · 2025Article
- BCAP Is an Interferon-Stimulated Gene That Enhances Type I Interferon Activity in Response to Lipopolysaccharide.International journal of molecular sciences · 2025Article
- Innate biosignature of treatment failure in human cutaneous leishmaniasis.Nature communications · 2025Article
- Type I interferon signature: a quantitative standardized method for clinical application.Clinical and experimental immunology · 2025Article
- Comprehensive transcriptome assessment in PBMCs of post-COVID patients at a median follow-up of 28 months after a mild COVID infection reveals upregulation of JAK/STAT signaling and a prolonged immune response.Frontiers in immunology · 2025Article
- Innate biosignature of treatment failure in human cutaneous leishmaniasis.Research square · 2024Article
- Rheumatological complaints in H syndrome: from inflammatory profiling to target treatment in a case study.Pediatric rheumatology online journal · 2024Article
- Siglec-1, an easy and contributory inflammation marker in rheumatology.Clinical & translational immunology · 2024Article
- Inflammation and Interferon Signatures in Peripheral B-Lymphocytes and Sera of Individuals With Fibromyalgia.Frontiers in immunology · 2022Article
- Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives.International journal of molecular sciences · 2021Review
- Genetic and immunologic findings in children with recurrent aphthous stomatitis with systemic inflammation.Pediatric rheumatology online journal · 2021Article
- Priming of the cGAS-STING-TBK1 Pathway Enhances LPS-Induced Release of Type I Interferons.Cells · 2021Article
- Type I Interferonopathies in Children: An Overview.Frontiers in pediatrics · 2021Review
- Lung involvement in monogenic interferonopathies.European respiratory review : an official journal of the European Respiratory Society · 2020Article
- Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.Journal for immunotherapy of cancer · 2020Article
- Higher interferon score and normal complement levels may identify a distinct clinical subset in children with systemic lupus erythematosus.Arthritis research & therapy · 2020Article
- Pediatrics: An Evolving Concept for the 21st Century.Diagnostics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Interferon-stimulated genes (ISGs) are a set of genes whose transcription is induced by interferon (IFN). The measure of the expression of ISGs enables calculating an IFN score, which gives an indirect estimate of the exposition of cells to IFN-mediated inflammation. The measure of the IFN score is proposed for the screening of monogenic interferonopathies, like the Aicardi-Goutières syndrome, or to stratify subjects with systemic lupus erythematosus to receive IFN-targeted treatments. Apart from these scenarios, there is no agreement on the diagnostic value of the score in distinguishing IFN-related disorders from diseases dominated by other types of cytokines. Since the IFN score is currently measured in several research hospitals, merging experiences could help define the potential of scoring IFN inflammation in clinical practice. However, the IFN score calculated at different laboratories may be hardly comparable due to the distinct sets of IFN-stimulated genes assessed and to different controls used for data normalization. We developed a reliable approach to minimize the inter-laboratory variability, thereby providing shared strategies for the IFN signature analysis and allowing different centers to compare data and merge their experiences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.